左心房尾关闭与口服抗凝剂用于心房中风预防:来自4项随机试验的长期结果
Wulamiding Kaisaier1, Zixuan Xu2, Linjuan Guo3
1Department of Cardiology, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, PR China.
Heart rhythm
|August 3, 2025
概括
与口服抗凝剂 (OAC) 相比,左心房尾关闭 (LAAC) 在心房患者中减少了死亡和出血事件. 这项分析表明,LAAC是预防精选AF患者中风的安全替代方案.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 医疗器械技术 医疗器械技术
背景情况:
- 左心房尾关闭 (LAAC) 是一种替代性中风预防策略,用于无法使用口服抗凝剂 (OAC) 的心房动 (AF) 患者.
- 在更广泛的AF人群中,LAAC和OAC之间的长期比较有效性数据有限.
研究的目的:
- 评估LAAC与OAC在AF患者中风预防方面的长期疗效和安全性.
- 进行随机对照试验 (RCT) 的元分析,以比较这些治疗策略.
主要方法:
- 在PubMed,Embase和Cochrane图书馆系统地搜索相关RCT的文献.
- 使用固定效应模型来计算风险比率 (RR) 和95%置信区间 (CI) 的元分析.
- 包括4个RCT,包括3116名AF患者,随访时间长达49.6个月.
主要成果:
- 与OAC相比,LAAC显示所有原因死亡 (RR=0.78) 和心血管/不明原因死亡 (RR=0.69) 的风险降低.
- 使用LAAC显著降低了出血性中风 (RR=0.34) 和非程序性出血 (RR=0.49) 的风险.
- 在中风,缺血性中风,全身血栓塞或非心血管死亡率方面没有显著差异;重大出血风险相似.
结论:
- 与OAC相比,LAAC与死亡,出血性中风和非程序性出血的风险明显降低.
- 拉克不增加血栓栓塞事件或重大出血的风险.
- 研究结果支持LAAC作为一种可行的OAC替代品,用于预防精选的AF患者中风.
相关概念视频
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22
Anticoagulant Drugs: Low-Molecular-Weight Heparins
909
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
909
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K


